(Q51703728)

English

Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.

scientific article published on 10 August 2014

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/25127173

Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/25127173

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

monoclonal antibody

1 reference

based on heuristic

inferred from title

Peter J. Goadsby

2

object named as

Peter J Goadsby

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

1

object named as

David W Dodick

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

author name string

Egilius L H Spierings

3

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/25127173

Joel C Scherer

4

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/25127173

Steven P Sweeney

5

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/25127173

David S Grayzel

6

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/25127173

publication date

10 August 2014

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/25127173

Lancet Neurology

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/25127173

13

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/25127173

9

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/25127173

885-892

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/25127173

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Global prevalence of chronic migraine: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Concepts and mechanisms of migraine chronification

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic migraine, classification, differential diagnosis, and epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Modifiable risk factors for migraine progression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic migraine--classification, characteristics and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic prospects for migraine: can paradise be regained?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Calcitonin gene-related peptide (CGRP) and its receptor components in human and rat spinal trigeminal nucleus and spinal cord at C1-level

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distrib

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Pearls and pitfalls in neural CGRP immunohistochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

CGRP may play a causative role in migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Humanized antibodies and their applications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

International Classification of Headache Disorders, Second Edition (ICHD-2): current status and future revisions.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Topiramate for migraine prevention: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Topiramate in migraine prevention: results of a large controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Headache: the Placebo Effects in the Control Groups in Randomized Clinical Trials; an Analysis of Systematic Reviews

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The importance of placebo in headache research

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

CGRP and its receptors provide new insights into migraine pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Possible site of action of CGRP antagonists in migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

CSD, BBB and MMP-9 elevations: animal experiments versus clinical phenomena in migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Cortical spreading depression activates and upregulates MMP-9.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The use of migraine preventive medications among patients with and without migraine headaches

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Expert opinion: adherence to prophylactic migraine medication.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Modifiable risk factors for migraine progression (or for chronic daily headaches)--clinical lessons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The International Burden of Migraine Study (IBMS): study design, methodology, and baseline cohort characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Confidence intervals

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970128-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(14)70128-0

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/25127173

release_osu6oipgzjalhgtprgpmrvyeoy

1 reference

https://api.fatcat.wiki/v0/release/osu6oipgzjalhgtprgpmrvyeoy

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 April 2018

http://europepmc.org/abstract/MED/25127173

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51703728&oldid=1843863280"